Exercise4

Structure Therapeutics Inc.

Total Value

$4.0K

Filing Date

Aug 19, 2026

1 transactions

Trade Summary

On Aug 18, 2026, Lin Xichen, Insider, reported $4.0K of Structure Therapeutics Inc. (GPCR) across 1 transactions. The filing covers Ordinary Shares and reflects balanced net activity of $0. Reported prices ranged from $0.34. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Lin Xichen
Role: Insider
Location: SOUTH SAN FRANCISCO, CA

Filing Details

Filing Date: Aug 19, 2026
Transaction Date: Aug 18, 2026
Accession Number: 0001962926-26-000008
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 18, 2026	Ordinary Shares	11,817	$0.34	Exercise	$4.0K
Aug 18, 2026	Ordinary Shares	11,817	—	C	—

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 18, 2026	GPCR derivative	11,817	—	Exercise	—
Aug 18, 2026	GPCR derivative	3,939	—	C	—
Aug 18, 2026	GPCR derivative	3,020	—	Sale	—
Aug 18, 2026	GPCR derivative	519	—	Sale	—
Aug 18, 2026	GPCR derivative	400	—	Sale	—

Want live alerts when Lin Xichen trades again?

Download Insider Trades to track GPCR, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Reflects price per share in Ordinary Shares.
(F2)The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
(F3)1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
(F4)This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 11,817 Ordinary Shares.
(F5)Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
(F6)11,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 3,939 American Depositary Shares.
(F7)The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
(F8)Reflects price per share in American Depositary Shares.
(F9)The weighted average sale price for the transaction reported was $53.133 and the range of prices were between $52.77 and $53.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
(F10)The weighted average sale price for the transaction reported was $54.1970, and the range of prices were between $53.80 and $54.7950. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
(F11)The weighted average sale price for the transaction reported was $55.05 and the range of prices were between $54.85 and $55.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Xichen

(Last)

(First)

(Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/18/2026		M		11,817	A	$0.34⁽¹⁾	240,777	D
Ordinary Shares	08/18/2026		C		11,817⁽²⁾	D	$0	228,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$0.34⁽¹⁾	08/18/2026		M			11,817	⁽³⁾	09/10/2029	Ordinary Shares	11,817	$0	142,898⁽⁴⁾	D
American Depositary Shares	⁽⁵⁾	08/18/2026		C		3,939⁽⁶⁾		⁽⁵⁾	⁽⁵⁾	Ordinary Shares	11,817	$0	3,939	D
American Depositary Shares	⁽⁵⁾	08/18/2026		S⁽⁷⁾			3,020	⁽⁵⁾	⁽⁵⁾	Ordinary Shares	9,060	$53.133⁽⁸⁾⁽⁹⁾	919	D
American Depositary Shares	⁽⁵⁾	08/18/2026		S⁽⁷⁾			519	⁽⁵⁾	⁽⁵⁾	Ordinary Shares	1,557	$54.197⁽⁸⁾⁽¹⁰⁾	400	D
American Depositary Shares	⁽⁵⁾	08/18/2026		S⁽⁷⁾			400	⁽⁵⁾	⁽⁵⁾	Ordinary Shares	1,200	$55.05⁽⁸⁾⁽¹¹⁾	0	D

Explanation of Responses:

1. Reflects price per share in Ordinary Shares.

2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.

3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 11,817 Ordinary Shares.

5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.

6. 11,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 3,939 American Depositary Shares.

7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.

8. Reflects price per share in American Depositary Shares.

9. The weighted average sale price for the transaction reported was $53.133 and the range of prices were between $52.77 and $53.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

10. The weighted average sale price for the transaction reported was $54.1970, and the range of prices were between $53.80 and $54.7950. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

11. The weighted average sale price for the transaction reported was $55.05 and the range of prices were between $54.85 and $55.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

	/s/ Jun Yoon, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001962926-26-000008.

Structure Therapeutics Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Lin Xichen trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4